申请人:Kaken Pharmaceutical Co., Ltd.
公开号:EP1325914A1
公开(公告)日:2003-07-09
Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients:
通式(I)的四氢喹啉化合物或其药理学上可接受的盐类,它们与AR具有特异性强的结合亲和力,表现出AR激动或拮抗作用,对AR介导的疾病具有治疗作用,特别是作为AR激动剂不会对前列腺产生过度作用,但对骨骼肌组织和骨组织表现出强效作用;以及包含这些化合物或盐类作为活性成分的药物组合物: